Simultaneous application of bevacizumab and anti-CTGF antibody effectively suppresses proangiogenic and profibrotic factors in human RPE cells. [electronic resource]
Producer: 20150911Description: 378-90 p. digitalISSN:- 1090-0535
- Actins -- genetics
- Angiogenesis Inhibitors -- pharmacology
- Antibodies, Monoclonal, Humanized -- pharmacology
- Antibodies, Neutralizing -- pharmacology
- Apoptosis -- drug effects
- Bevacizumab
- Cathepsin D -- genetics
- Cell Proliferation -- drug effects
- Connective Tissue Growth Factor -- antagonists & inhibitors
- Drug Synergism
- Epithelial Cells -- cytology
- Gene Expression Regulation
- Humans
- Matrix Metalloproteinase 2 -- genetics
- Matrix Metalloproteinase 9 -- genetics
- Primary Cell Culture
- Retinal Pigment Epithelium -- cytology
- Signal Transduction
- Tissue Inhibitor of Metalloproteinase-1 -- genetics
- Tissue Inhibitor of Metalloproteinase-2 -- genetics
- Transcription, Genetic
- Vascular Endothelial Growth Factor A -- antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-1 -- genetics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.